Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers

International Journal of Gynecological Cancer

Volumn 21, Issue 4, 2011, Pages 633-639

  Kelly, Michael G ^a   Mor, Gil ^b   Husband, Alan ^c   O'Malley, David M ^d   Baker, Lisa ^b   Azodi, Masoud ^b   Schwartz, Peter E ^b   Rutherford, Thomas J ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Chemotherapy; Ovarian cancer; Phenoxodiol

Indexed keywords

CISPLATIN; IDRONOXIL; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG FATALITY; FALLOPIAN TUBE CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEMALE GENITAL TRACT CANCER; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; IMMUNOTOXICITY; INFECTION; LEUKOPENIA; MENTAL DISEASE; METABOLIC DISORDER; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PAIN; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SKIN TOXICITY; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; ISOFLAVONES; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; PLATINUM COMPOUNDS; TAXOIDS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 80051873080     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182126f05     Document Type: Article

References (25)

1. Schwartz PE. Current diagnosis and treatment modalities for ovarian cancer. Cancer Treat Res. 2002;107:99-118.
2. American Cancer Society. Cancer Facts and Figures 2009. Available at: http://www.cancer.org. Accessed November 8, 2010.
3. Kaye SB. Chemotherapy for recurrent ovarian cancer. Lancet. 2003;361:2094-2095. (Pubitemid 36782247)
4. Engel J, Eckel R, Schubert-Fritschle G, et al. Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. Eur J Cancer 2002;38:2435-2445. (Pubitemid 35387497)
5. Seiden MV. Ovarian cancer. Oncologist. 2001;6:327-332. (Pubitemid 32816536)
6. Yusuf RZ, Duan Z, Lamendola DE, et al. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets. 2003;3:1-19. (Pubitemid 36119417)
7. Millar AW, Lynch KP. Rethinking clinical trials for cytostatic drugs. Nat Rev Cancer. 2003;3:540-545. (Pubitemid 37328842)
8. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3:502-516. (Pubitemid 37328838)
9. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 2000;256:42-49. (Pubitemid 30211165)
10. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol. 2002;71:907-920.
11. Fraser M, Leung B, Jahani-Asl A, et al. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod Biol Endocrinol. 2003;1:66.
12. Sapi E, Chen W, O'Malley D, et al. Resistance of ovarian cancer cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Anticancer Drugs. 2004;14:567-578. (Pubitemid 40178958)
13. Lamendola DE, Duan Z, Yusuf RZ, et al. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Res. 2003;63:2200-2205. (Pubitemid 36538627)
14. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002;2:277-288. (Pubitemid 37328781)
15. Kamsteeg M, Rutherford T, Sapi E, et al. PhenoxodiolVan isoflavone analogueVinduces apoptosis in chemo-resistant ovarian cancer cells. Oncogene. 2003;22:2611-2620. (Pubitemid 36605609)
16. Alvero AB, O'Malley D, Brown D, et al. Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer. 2006;106:599-608. (Pubitemid 43157623)
17. Aguero MF, Facchinetti MM, Sheleg Z, et al. Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1. Cancer Res. 2005;65: 3364-3373. (Pubitemid 40524621)
18. Mor G, Fu HH, Alvero AB. Phenoxodiol, a novel approach for the treatment of ovarian cancer. Curr Opin Investig Drugs. 2006;7:542-548. (Pubitemid 43891033)
19. Choueiri TK, Mekhail T, Hutson TE, et al. Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. Ann Oncol. 2006;17:860-865.
20. de Souza PL, Liauw W, Links M, et al. Phase I and pharmacokinetic study of weekly NV06 (Phenoxodiol), a novel isoflav-3-ene, in patients with advanced cancer. Cancer Chemother Pharmacol. 2006;58:427-433. (Pubitemid 43999790)
21. Rutherford T, O'Malley D, Makkenchery A, et al. Phenoxodiol phase Ib/II study in patients with recurrent ovarian cancer that are resistant to Q second line chemotherapy. J Soc Gynecol Investig. 2004;11:254.
22. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003. Available at: http://ctep.cancer.gov. Accessed August 9, 2006.
23. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate response to treatment in solid tumours. J Natl Cancer Inst. 2000;92:205-216. (Pubitemid 30099779)
24. Rustin GJ, Nelstrop AE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol. 1996;14:1545-1551. (Pubitemid 26134212)
25. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989;111:273-279. (Pubitemid 19204753)